LeMaitre Vascular, Inc. filings document a Nasdaq-listed medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Recent Form 8-K reports furnish quarterly operating and financial results, dividend-related updates, and related press release exhibits.
Proxy and governance filings cover board structure, director elections, executive compensation, advisory say-on-pay matters, and shareholder voting results. The filings also identify the company’s common stock, par value, Nasdaq Global Market listing under LMAT, and related public-company disclosure controls.
LeMaitre Vascular’s Chairman and CEO, George W. LeMaitre, reported routine compensation-related awards rather than market trades. On March 26, 2026, he acquired several blocks of dividend equivalent rights, each economically equal to one share of LeMaitre Vascular common stock.
The rights accrued automatically on earlier restricted stock unit and performance share unit awards granted in December 2022, 2023, and 2024, and they will vest proportionately with those underlying awards. No open-market buying or selling occurred, and the transactions do not change cash holdings.
The Vanguard Group filed Amendment No. 6 to a Schedule 13G/A reporting its holdings in LeMaitre Vascular Inc. The amendment states 0% beneficial ownership and 0 shares beneficially owned as of the filing, following an internal realignment on 01/12/2026 that disaggregated certain subsidiaries' holdings.
The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026. It affirms that no single third party holds more than 5% of the class among accounts aggregated by Vanguard.
LeMaitre Vascular senior vice president Trent G. Kamke exercised stock options and sold the resulting shares. He exercised options for 2,625 shares of common stock at an exercise price of $35.48 per share, then sold 2,625 shares at $108.50 per share, leaving 6,677 shares owned directly.
LeMaitre Vascular’s President and Director David B. Roberts reported an open-market sale of 3,311.68 shares of common stock on March 11, 2026 at a weighted average price of $107.6752 per share. After this transaction, he directly holds 14,667.32 shares of the company’s common stock.
The sale was executed in multiple trades at prices ranging from $106.52 to $108.65, with the weighted average reported. Roberts has undertaken to provide detailed trade and pricing information to the company, its shareholders, or the SEC staff upon request.
LeMaitre Vascular’s Chief Financial Officer Dorian Paul LeBlanc reported routine equity compensation activity. On March 10, 2026, he exercised dividend equivalent rights into 2 shares of common stock at $0.00 per share and now holds 9.3269 dividend equivalent rights. He also holds 2,302 shares of common stock directly after these transactions.
The filing shows 96 shares of common stock were withheld at $109.20 per share to satisfy tax obligations on restricted stock units that vested from an award granted on March 10, 2025. The tax withholding is characterized as an exempt sale under Rule 16b-3(e) and does not reflect an open-market trade.
LMAT files a Form 144 to offer 2,625 shares of Common Stock for sale. The notice states the planned sale arises from a stock option exercise and is dated 03/11/2026.
The filing also records a prior sale of 1,044 shares on 02/27/2026 by Trent G. Kamke for $115,142.76.
LeMaitre Vascular Inc. is the issuer for Officer David B. Roberts’s proposed sale of 3,312 common shares, listed at an aggregate market value of $357,893 and an approximate sale date of March 11, 2026. The account is registered to David B. Roberts as trustee of the David B. Roberts 2003 Trust. The shares were acquired from the issuer through stock option exercises and RSU grants. The notice also lists David B. Roberts’s sale of 8,464 shares on February 27, 2026, for gross proceeds of $903,957.
LeMaitre Vascular director Martha Shadan reported equity-based compensation on common stock. On February 26, 2026, she acquired 476 shares of common stock at a price of $0.0000 per share as a grant or award. She also acquired 1 additional common share through the exercise of a dividend equivalent right linked one-for-one to common stock. These transactions stem from a Performance Share Unit award originally granted on December 6, 2024, which vested one-third upon satisfaction of its performance condition on February 26, 2026, with the remaining portions scheduled to vest in equal annual installments on the grant date anniversaries over the next two years.
LeMaitre Vascular director John A. Roush reported equity awards and vesting activity, not open‑market trades. On February 26, 2026, he received a grant of 476 shares of common stock and 1 share from the exercise of dividend equivalent rights, bringing his directly held common stock to 3,942 shares. Related derivative dividend equivalent rights totaled 2.8963 following settlement linked to a Performance Share Unit (PSU) award granted on December 6, 2024, which vested one‑third when the performance condition was met, with the remainder vesting in equal annual installments over the next two years. An additional 181 shares are held indirectly by his spouse.
LeMaitre Vascular director Bridget A. Ross reported acquiring company stock through equity awards. On February 26, 2026 she received 476 shares of common stock upon partial vesting of a performance share unit award, plus 1 share released from dividend equivalent rights, bringing her direct holdings to 3,942 shares.